Credence

University of Sydney Researchers Develop Nasal mRNA Approach to Protect Against Alzheimer's-Related Cognitive Decline


Key Points

  • Nasal mRNA lipid nanoparticles delivering BDNF improved memory in aged mice and prevented decline in Alzheimer's model mice
  • BDNF protein was detected for up to four days after a single dose, and hippocampal doublecortin-expressing cells rose to 2.4 times control levels
  • The approach supports neuronal survival without reducing amyloid-beta, potentially complementing existing antibody therapies

Researchers at the University of Sydney have developed an experimental mRNA-based therapy designed to protect brain function and prevent memory loss associated with Alzheimer’s disease. Delivered through nasal drops, the technology uses lipid nanoparticles to transport messenger RNA (mRNA) encoding brain-derived neurotrophic factor (BDNF), a protein involved in neuron survival, growth and memory formation.

In preclinical studies, the approach improved memory performance in aged mice and prevented cognitive decline in mice genetically engineered to develop Alzheimer’s-like symptoms. The findings, published in Advanced Science, could open another avenue for applying mRNA technology beyond infectious diseases to neurological disorders.

The research team, led by Professor Greg Neely, developed the treatment to address declining BDNF levels in brain regions associated with learning and memory, particularly the hippocampus and entorhinal cortex. Rather than administering the BDNF protein directly, the researchers used mRNA to instruct cells to produce the protein themselves.

The delivery system encapsulates BDNF-encoding mRNA in lipid nanoparticles, similar to the technology used in mRNA-based COVID-19 vaccines. The formulation is administered as nasal drops, allowing the therapeutic material to enter through the nasal mucosa and reach the brain without relying on conventional delivery across the blood-brain barrier.

BDNF plays an important role in maintaining neuronal health and supporting the connections between brain cells that underpin learning and memory. However, delivering the protein directly as a therapeutic has presented challenges, including rapid degradation in the nasal environment and limitations on the amount that can be administered.

The Sydney team’s approach instead uses mRNA to promote local production of BDNF following administration. Researchers detected the resulting protein for as long as four days after a single dose. The nasal route is also intended to bypass the blood-brain barrier, a protective system formed by specialized endothelial cells surrounding brain blood vessels that restricts the passage of many drugs and large molecules.

In the animal studies, aged mice receiving the treatment demonstrated improvements in memory tasks, including recognizing unfamiliar objects and remembering specific locations. Researchers also observed increased neuronal numbers in the hippocampus. In 18-month-old mice, memory performance improved to levels comparable with younger animals. The number of hippocampal cells expressing doublecortin (DCX), a protein associated with the development of new neurons, increased to 2.4 times the level observed in untreated control animals.

The researchers also evaluated the treatment in genetically modified mice that develop Alzheimer’s-like pathology. Animals received the nasal formulation twice weekly beginning at two months of age. While untreated disease-model mice typically showed substantial cognitive decline by four months, the treated animals did not demonstrate the same decline during the study period.

The experimental therapy works through a different biological mechanism than currently available Alzheimer’s antibody treatments, which primarily target amyloid-beta plaques. Rather than attempting to remove amyloid-beta accumulation, the BDNF mRNA approach is designed to support neuronal survival and function. Notably, the researchers observed improvements in cognitive performance without a reduction in amyloid-beta deposits in the treated animals.

This distinction suggests the technology could potentially complement existing amyloid-targeting therapies rather than replace them. Combining approaches that address disease-associated protein accumulation with treatments aimed at maintaining neuronal health could offer additional therapeutic opportunities. Researchers say the findings demonstrate the potential for mRNA therapeutics to extend into neurological disease treatment beyond their established applications in infectious diseases. The approach could eventually have applications across other neurodegenerative conditions.

Learn more at www.sydney.edu.au/.